ALB and glomerulosclerosis: As expected, adriamycin (ADR) treatment caused severe glomerular sclerosis (Fig. 1B), elevated urinary albumin excretion (Fig. 1C), and reduced body weight (Fig. S1a) compared with the control group (CON).